Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (vol 29, pg 2835, 2023)

被引：0

作者：

Kirkwood, John M. ^{[1
]}

Del Vecchio, Michele ^{[2
]}

Weber, Jeffrey ^{[3
]}

Hoeller, Christoph ^{[4
]}

Grob, Jean-Jacques ^{[5
]}

Mohr, Peter ^{[6
]}

Loquai, Carmen ^{[7
]}

Dutriaux, Caroline ^{[8
]}

Chiarion-Sileni, Vanna ^{[9
]}

Mackiewicz, Jacek ^{[10
]}

Rutkowski, Piotr ^{[11
,12
,13
]}

Arenberger, Petr

Quereux, Gaelle ^{[14
]}

Meniawy, Tarek M. ^{[15
,16
]}

Ascierto, Paolo A. ^{[17
]}

Menzies, Alexander M. ^{[18
,19
]}

Durani, Piyush ^{[20
]}

Lobo, Maurice ^{[20
]}

Campigotto, Federico ^{[20
]}

Gastman, Brian ^{[21
]}

Long, Georgina V. ^{[18
,19
]}

机构：

[1] UPMC Hillman Canc Ctr, Pittsburgh, PA 15232 USA

[2] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[3] NYU Langone Med Ctr, New York, NY USA

[4] Med Univ Wien, Vienna, Austria

[5] Hop La Timone, Marseille, France

[6] Elbe Klinikum Buxtehude, Buxtehude, Germany

[7] Univ Med Ctr Mainz, Mainz, Germany

[8] Hop St Andre, Bordeaux, France

[9] IOV IRCCS, Ist Oncol Veneto, Padua, Italy

[10] Poznan Univ Med Sci, Inst Oncol, Poznan, Poland

[11] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[12] Charles Univ Prague, Fac Med 3, Prague, Czech Republic

[13] Univ Hosp Kralovske Vinohrady, Prague, Czech Republic

[14] Nantes Univ Hosp, Nantes, France

[15] Univ Western Australia, Perth, WA, Australia

[16] Charles Gairdner Hosp, Perth, WA, Australia

[17] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy

[18] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia

[19] Royal North Shore & Mater Hosp, Sydney, NSW, Australia

[20] Bristol Myers Squibb, Princeton, NJ USA

[21] Cleveland Clin, Cleveland, OH USA

来源：

NATURE MEDICINE | 2024年 / 30卷 / 03期

关键词：

D O I：

10.1038/s41591-023-02775-w

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：906 / 906

页数：1

共 35 条

[31] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial (vol 23, pg 888, 2022)
Vergote, I
Gonzalez-Martin, A.
Lorusso, D.
LANCET ONCOLOGY, 2022, 23 (09): : E404 - E404
[32] Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for PatientsWith Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial (vol 36, pg 1469, 2018)
Andre
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18) : 1893 - 1893
[33] Primary Overall Survival (OS) from OPTiM, a Randomized Phase 3 Trial of Talimogene Laherparepvec (T-VEC) versus Subcutaneous (SC) Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for the Treatment of Unresected Stage IIIB/C/IV Melanoma
Kaufman, H.
Andtbacka, R. H.
Collichio, F.
Amatruda, T.
Senzer, N.
Chesney, J.
Delman, K.
Spitler, L. E.
Puzanov, I.
Ye, Y.
Li, A.
Gansert, J.
Coffin, R.
Ross, M.
ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S126 - S126
[34] High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801 (vol 19, pg 2370, 2001)
Kirkwood
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) : 3443 - 3443
[35] Blauvelt A, Ladizinski B, Prajapati VH, Laquer V, Fischer A, Eisman S, Hu X, Wu T, Calimlim BM, Kaplan B, Liu Y, Teixeira HD, Liu J, Eyerich K. Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up). J Am Acad Dermatol. (vol 89, pg 478- 485, 2023)
Blauvelt, A.
Ladizinski, B.
Prajapati, Vh
Laquer, V
Fischer, A.
Eisman, S.
Hu, X.
Wu, T.
Calimlim, Bm
Kaplan, B.
Liu, Y.
Teixeira, Hd
Liu, J.
Eyerich, K.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (03)

← 1 2 3 4 →